A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination with GSK2141795 in Patients with Advanced Uveal Melanoma (NCI #9445)
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2018
Price : $35 *
At a glance
- Drugs Trametinib (Primary) ; Uprosertib (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 25 Jan 2018 Status changed from active, no longer recruiting to completed.
- 07 Mar 2017 Status changed from recruiting to active, no longer recruiting.